

Attomarker

Gold standard rapid diagnostics



Attomarker is a diagnostics company with a unique proprietary nanotechnology that measures multiple human (and animal) biomarkers rapidly off a single small sample. This will revolutionise diagnostic technology, providing the opportunity for multi-dimensional dynamic testing, utilising AI and the potential big data, and enable early medical intervention for longer, healthier lives.

Overview

- Attomarker is a med-tech company that specialises in the development and commercialisation of cutting-edge diagnostic technologies.
- Founded by Professor Andrew Shaw, Attomarker is a spin-out from the University of Exeter, and his second spin-out company with the first sold for \$8m.
- Attomarker has a novel finger-prick blood testing CE-marked technology.
- Attomarker focuses on creating innovative point-of-care devices and essays that enable rapid and accurate detection of various diseases and conditions.
- Attomarker's mission is to improve global healthcare by providing affordable and accessible diagnostic solutions.
- Attomarker's core technology revolves around a multi-patented multiplexed biophotonic sensor array exploiting the attributes of gold nanoparticles, enabling the rapid simultaneous detection of multiple biomarkers from a single small sample.

Technology & Business Model

- Number of patents: 8
- Number of research publications: 50+
- Attomarker's current flagship product is the Attomarker Liscar 6: a compact and portable benchtop diagnostic device that integrates advanced microfluidics, biosensors, and signal amplification technologies.
- The Liscar 6 is designed to perform multiple tests simultaneously on a single platform, providing rapid results within minutes.
- One of Attomarker's key advantages is its ability to develop sensitive and specific tests using minimal sample volumes.
- This makes the technology ideal to support human and animal healthcare in resource-limited settings, rural areas, and point-of-care environments where access to sophisticated laboratory infrastructure is limited.

Key Takeaway

Rapid Market Readiness of Biomarker Panels for Diagnostic and Companion Diagnostics

- Overall Market predicted to grow to \$78bn by 2026 with CAGR of 12.6%

Attomarker Pipeline

- Infant food allergy, advanced liver function, precision fertility and menstrual cycle monitoring, HRT and 9 others

Team

SENIOR EXEC TEAM



Andrew Shaw
CEO & Founder

Attomarker is Prof Shaw's second spin-out company, the first having been sold for \$8M



Jonathan Snicker
Chief Strategy Officer

20+ years' experience in variety of roles spanning university academia, business development, philanthropy, strategic, political, comms and funding advisory



Andrew Vincent
Global Marketing Director

20+ years' experience in international strategic & operational healthcare marketing and business development. Director of Integra Healthcare Ltd



Robert Warner
Chief Financial Officer

Chartered Accountant from KPMG, with 20 years' experience as a commercial CFO, gained across a variety of rapid-scale international businesses in diverse sectors



Jonathan Collins
General Counsel

Seasoned lawyer with international corporate and commercial experience. Previously: Jones Day, JP Morgan and Jardine Matheson

Valuation

		2026	2027
EBITDA	EBITDA/M	£24	£60
Multiple (18x)	Valuation/M	£434	£1073
DCF Multiple	WACC 15% of 2027 Turnover	£102m	

ROI on a £30m Investment: 10x – 20x in 5 years

Fundraising

- Attomarker is raising £30m for its Series A.
- Previously, Attomarker has raised £3m in its seed round and £1.5m during the COVID pandemic.
- Series A fundraising will be targeted towards global expansion: Development and Production (£30m), Global Regulatory Presence (£5m) and Sales, Marketing Customer Care (£8m)
- Global distribution will be supported through strategic partnerships with Innova Medical Group and attoCaribbean.

Pipeline

- In addition to their partnership with Re:Cognition Health, Attomarker have formed an alliance with Carus Animal Health to develop their handheld instrument and to provide biomarker tests to the vet market.
- Together, the device and assays will cover a broad range of medical conditions, including infectious diseases, NCDs, cardiovascular disorders, cancer biomarkers, autoimmune diseases, and hormonal imbalances.



5th Generation HIV




Indoor Allergens



Outdoor Allergens



Sepsis



Women's Health & Fertility



Type 1 Diabetes



Nut Allergens



Food Allergens I, II, III



Hepatitis A, B, C



Emergency Room Triage



Vaccination Panel



Wellness Panel



Alzheimer's Test



Immunotherapy Cohort surveillance

Impact

- **Global Impact:** Antimicrobial resistance and disease diagnosis in lower- and middle-income countries.



About Milltrust International

With its mantra of “Sustainable Prosperity”, Milltrust International Group is a global investment organisation making sustainable impact investments in the biggest themes of our generation: climate change, the demand for food and protein, the future of medical technology, and the rise of the developing world.

Over the past decade, Milltrust has assembled a highly experienced team of leading industry professionals focused exclusively on providing investment management expertise on both public and private markets.

Milltrust’s private investments consist of a plethora of science-backed early-stage disruptive companies in the space of climate impact, healthcare, and agriculture. By drawing on the experience of investment bankers, asset managers, healthcare professionals, and agronomists, our diversified assets have pioneered breakthrough technology in environmental management, medical diagnostics, and animal genetics and welfare with the aim of delivering sustainable solutions an ever-growing and increasingly ageing global population.

About The British Innovation Fund II

The British Innovation Fund II follows on from the success of The British Innovation Fund I, investing into high potential companies with a focus on agri-tech, the future of healthcare, climate impact, and alternative protein, where incontrovertible science is at the core of the commercial proposition.

More Information

Milltrust International UK

6 Stratton Street
London W1J 8LD
United Kingdom

+44 (0)20 8123 8316

info@milltrust.com

Milltrust International Singapore

77B Tras Steet
Singapore 079016
Singapore

+65 6225 3052

info@milltrust.com

Signatory of:



Disclaimer

For professional investors only. This document is strictly private and confidential and is meant as guidance and information only. It is issued by Milltrust International LLP which is authorised and regulated by the Financial Conduct Authority in the United Kingdom. Milltrust International LLP has its registered office at 5 Market Yard Mews, 194-204 Bermondsey Street, London, SE1 3TQ, United Kingdom and is a subsidiary of Milltrust International Group (Singapore) Pte Ltd. Milltrust Ventures Pte Ltd is a subsidiary of Milltrust International Group (Singapore) Pte. Ltd and is registered with the Monetary Authority of Singapore as a Venture Capital Fund Management Company (VCFM). The content in this document is for informational purposes only and does not constitute legal, tax, investment, financial, or other advice. Nothing contained in this document constitutes a solicitation, recommendation, endorsement, or offer by Milltrust International LLP or any of its affiliates to buy or sell any securities or other financial instruments. No such solicitation or offer is made in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. All content in this document is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in the document constitutes professional and/or financial advice, nor does any information on the document constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. It should therefore not be used as the sole basis for any investment or other decision. The use of or access to this document or content by any person does not create a fiduciary relationship between such person and Milltrust International LLP. The sole responsibility of evaluating the merits and risks associated with the use of any information or other content on this document before making any decisions based on such information or other content rests with the user and their professional advisers. Notice to US investors: The shares of Milltrust International Managed Investments ICAV have not been registered under the 1933 Securities Act or under the 1940 Act; however, the company takes advantage of the 3(c)7 exemption and shares are available to 3(C)(1) US “qualified purchasers” and those qualifying under Reg D. Distribution activity in the US is undertaken by Silverleaf Partners LLC, a registered broker-dealer based in New York. Beyond providing initial capital for the companies we invest in, Milltrust may also leverage its extensive network to support our portfolio companies on a commercial basis with additional capital raises as they grow. Whether through introductions to potential investors, strategic partnerships, or other value-add services, we are committed to helping our portfolio companies succeed. Milltrust may receive compensation for services rendered to this company.